NEJM, Medscape, and Neil Floch MD highlight GLP-1s for diabetes and obesity, including safety summaries, new approvals, and long-acting formulations aiming for once or twice yearly dosing.
GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity
Novo Nordisk’s icodec-abae is now approved in the US for type 2 diabetes only
Weight-loss treatment may soon require far fewer injections
It is wonderful that GLP-1ra exist and have outstanding results
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare